Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 19
Treatment-assignment count: 0
Stratification count: 0
Cdx Established Context
ALK fusion
NSCLC · Monoclonal Antibody
ALK fusion is flagged as cdx established context because public trials show inclusion required evidence in 21 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 8
Common snippets: BRAF V600E | EGFR Exon 19 deletion | KRAS G12C
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT04837716 | https://clinicaltrials.gov/study/NCT04746924 | https://clinicaltrials.gov/study/NCT04310007 | https://clinicaltrials.gov/study/NCT07416058 | https://clinicaltrials.gov/study/NCT04591431 | https://clinicaltrials.gov/study/NCT03049618 | https://clinicaltrials.gov/study/NCT02367781 | https://clinicaltrials.gov/study/NCT07674368 | https://clinicaltrials.gov/study/NCT07393555 | https://clinicaltrials.gov/study/NCT04841538 | https://clinicaltrials.gov/study/NCT03958097 | https://clinicaltrials.gov/study/NCT05800015 | https://clinicaltrials.gov/study/NCT07082179 | https://clinicaltrials.gov/study/NCT04033354 | https://clinicaltrials.gov/study/NCT04507217 | https://clinicaltrials.gov/study/NCT06868836 | https://clinicaltrials.gov/study/NCT03952403 | https://clinicaltrials.gov/study/NCT03594747 | https://clinicaltrials.gov/study/NCT04244552 | https://clinicaltrials.gov/study/NCT03554473 | https://clinicaltrials.gov/study/NCT04300556